Лечащий Врач (Apr 2024)

IBS with constipation: new possibilities for drug therapy

  • M. V. Chernogorova,
  • E. A. Medvedeva,
  • G. L. Yurenev

DOI
https://doi.org/10.51793/os.2024.27.3.013
Journal volume & issue
Vol. 0, no. 3
pp. 76 – 83

Abstract

Read online

Background. Irritable bowel syndrome with a predominance of constipation is a common chronic pathology in the population. The main drug therapy for irritable bowel syndrome with a predominance of constipation remains the prescription of laxatives. One of the drugs with proven effectiveness is lactulose. However, taking into account the complaints of patients with irritable bowel syndrome with a predominance of constipation, it seems relevant to use drugs whose action is aimed at influencing several stages of pathogenesis and combating symptoms such as constipation, abdominal pain, bloating. These drugs include a combination drug based on lactulose and simethicone.Objective. The purpose of this study is to compare the effectiveness and safety of a combination drug based on lactulose and simethicone in comparison with a group receiving therapy in the form of a combination of two monotherapy drugs (lactulose and simethicone) and a group receiving lactulose monotherapy patients with irritable bowel syndrome with predominant constipation.Materials and methods. A single-stage open randomized comparative clinical trial was conducted from January 16, 2023 to June 29, 2023. The study included 150 patients diagnosed with irritable bowel syndrome with predominant constipation, aged 18 to 55 years, who were examined and treated for based on the State Budgetary Institution of the Ryazan Region "City Clinical Hospital No. 4", evenly randomized into 3 groups.Results. Fixed combination of lactulose + simeticone is superior in effectiveness to lactulose monotherapy in terms of stool frequency per week, stool shape, flatulence, and relief of abdominal pain. An additional analysis established the superior effectiveness of a drug based on lactulose and simethicone, an oral emulsion, in comparison with a combination of drugs simethicone, 40 mg capsules + lactulose syrup for the treatment of adult patients with irritable bowel syndrome with a predominance of constipation.

Keywords